Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure

In a randomized trial, more than 1100 patients with nonischemic heart failure (left ventricular ejection fraction ≤35%) were assigned either to receive or not to receive an ICD. At a median of 67.6 months, there was no significant difference in mortality between the two groups. In both European and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 375; H. 13; S. 1221 - 1230
Hauptverfasser: Køber, Lars, Thune, Jens J, Nielsen, Jens C, Haarbo, Jens, Videbæk, Lars, Korup, Eva, Jensen, Gunnar, Hildebrandt, Per, Steffensen, Flemming H, Bruun, Niels E, Eiskjær, Hans, Brandes, Axel, Thøgersen, Anna M, Gustafsson, Finn, Egstrup, Kenneth, Videbæk, Regitze, Hassager, Christian, Svendsen, Jesper H, Høfsten, Dan E, Torp-Pedersen, Christian, Pehrson, Steen
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 29.09.2016
Schlagworte:
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a randomized trial, more than 1100 patients with nonischemic heart failure (left ventricular ejection fraction ≤35%) were assigned either to receive or not to receive an ICD. At a median of 67.6 months, there was no significant difference in mortality between the two groups. In both European and U.S. guidelines, prophylactic implantation of an implantable cardioverter–defibrillator (ICD) is a class 1 recommendation for patients with heart failure and reduced left ventricular systolic function. 1 , 2 However, the evidence for a benefit is much stronger for patients with ischemic heart disease than it is for patients with heart failure from other causes. Over the past two decades, ICD implantation has been shown to be associated with substantial reductions in the rate of sudden cardiac death and total mortality in patients with ischemic heart disease. 3 – 6 In the case of patients without ischemic heart disease, one trial . . .
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1608029